Melanoma progression

Pathology

Volumn 48, Issue 2, 2016, Pages 147-154

  Elder, David E ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

dysplastic naevi; genomics; Melanoma; metastatic melanoma; naevi; progression; radial growth phase; vertical growth phase

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; DYSPLASTIC NEVUS; GENE MUTATION; GROWTH CURVE; HUMAN; MELANOCYTE; MELANOMA; METASTATIC MELANOMA; NONHUMAN; PIGMENTED NEVUS; COPY NUMBER VARIATION; DISEASE COURSE; DYSPLASTIC NEVUS SYNDROME; FEMALE; GENETICS; GENOMICS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN; SKIN NEOPLASMS;

DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; DYSPLASTIC NEVUS SYNDROME; FEMALE; GENOMICS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; SKIN; SKIN NEOPLASMS;

EID: 84975498168     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1016/j.pathol.2015.12.002     Document Type: Article

References (53)

1. P. Rous, and J.W. Beard The progression to carcinoma of virus-induced papillomas (Shope) J Exp Med 62 1935 523-48e
2. L. Foulds Neoplastic Development 1969 Academic Press London
3. B.C. Bastian The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia Annu Rev Pathol 9 2014 239 271
4. W.H. Clark Jr., D.E. Elder, D.I.V. Guerry, M.N. Epstein, M.H. Greene, and M. Van Horn A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma Hum Pathol 15 1984 1147 1165
5. A.H. Shain, I. Yeh, I. Kovalyshyn, and et al. The genetic evolution of melanoma from precursor lesions N Engl J Med 373 2015 1926 1936
6. I.W. Whimster Recurrent pigment cell naevi and their significance in the problem of endogenous carcinogenesis Ann Ital Dermatol Clin Sper 19 1965 168 191
7. J. Smolle, F.M. Smolle-Juettner, H. Stettner, and H. Kerl Relationship of tumor cell motility and morphologic patterns. Part 1. Melanocytic skin tumors Am J Dermatopathol 14 1992 231 237
8. C. Michaloglou, L.C. Vredeveld, M.S. Soengas, and et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi Nature 436 2005 720 724
9. D.C. Bennett Human melanocyte senescence and melanoma susceptibility genes Oncogene 22 2003 3063 3069
10. S. Tran, and H. Rizos Human nevi lack distinguishing senescence traits Aging (Albany NY) 5 2013 98 99
11. W.H. Clark Jr., R.R. Reimer, M.H. Greene, A.A. Ainsworth, and M.J. Mastrangelo Origin of familial melanomas from heritable melanocytic lesions. 'The B-K mole syndrome' Arch Dermatol 114 1978 732 738
12. D.E. Elder, L.I. Goldman, S.C. Goldman, M.H. Greene, and W.H. Clark Jr. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma Cancer 46 1980 1787 1794
13. M.H. Greene, W.H. Clark Jr., M.A. Tucker, and et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature Lancet 2 1980 1024
14. H.T. Lynch, B.C.I. Frichot, and J.F. Lynch Familial atypical multiple mole-melanoma syndrome J Med Genet 15 1978 352 356
15. A. Agusti-Mejias, F. Messeguer Badia, R. García Ruiz, V. Oliver Martínez, and V. Alegre de Miquel Atypical lentiginous nevus: a clinical and histopathologic study of 14 cases Actas Dermosifiliogr 103 2012 394 400
16. S. Kossard Atypical lentiginous junctional naevi of the elderly and melanoma Australas J Dermatol 43 2002 93 101
17. A.C. Halpern, D. Guerry, D.E. Elder, B. Trock, M. Synnestvedt, and T. Humphreys Natural history of dysplastic nevi J Am Acad Dermatol 29 1993 51 57
18. A.R. Rhodes, T.J. Harrist, C.L. Day, M.C. Mihm Jr., T.B. Fitzpatrick, and A.J. Sober Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas J Am Acad Dermatol 9 1983 563 574
19. C. Urso, V. Giannotti, U.M. Reali, B. Giannotti, and R. Bondi Spatial association of melanocytic naevus and melanoma Melanoma Res 1 1991 245 249
20. M.A. Tucker, A. Halpern, E.A. Holly, and et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma JAMA 277 1997 1439 1444
21. A.C. Halpern, D. Guerry, D.E. Elder, B. Trock, and M. Synnestvedt A cohort study of melanoma in patients with dysplastic nevi J Invest Dermatol 100 1993 346S 349S
22. M.A. Tucker, M.C. Fraser, A.M. Goldstein, D.E. Elder, D. Guerry, and S.M. Organic Risk of melanoma and other cancers in melanoma-prone families J Invest Dermatol 100 1993 350S 355S
23. M. Arumi-Uria, N.S. McNutt, and B. Finnerty Grading of atypia in nevi: correlation with melanoma risk Mod Pathol 16 2003 764 771
24. A.R. Shors, S. Kim, E. White, and et al. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma Br J Dermatol 155 2006 988 993
25. M.Y. Xiong, M.S. Rabkin, M.W. Piepkorn, and et al. Diameter of dysplastic nevi is a more robust biomarker of increased melanoma risk than degree of histologic dysplasia: a case-control study J Am Acad Dermatol 71 2014 1257 1258
26. A.G. Ayala, and J.Y. Ro Prostatic intraepithelial neoplasia: recent advances Arch Pathol Lab Med 131 2007 1257 1266
27. L. Strazzula, P. Vedak, M.P. Hoang, A. Sober, H. Tsao, and D. Kroshinsky The utility of re-excising mildly and moderately dysplastic nevi: a retrospective analysis J Am Acad Dermatol 71 2014 1071 1076
28. K.K. Reddy, M.J. Farber, J. Bhawan, R.G. Geronemus, and G.S. Rogers Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma JAMA Dermatol 149 2013 928 934
29. T.L. Hocker, A. Alikhan, N.I. Comfere, and M.S. Peters Favorable long-term outcomes in patients with histologically dysplastic nevi that approach a specimen border J Am Acad Dermatol 68 2013 545 551
30. M.V. Abello-Poblete, L.M. Correa-Selm, D. Giambrone, F. Victor, and B.K. Rao Histologic outcomes of excised moderate and severe dysplastic nevi Dermatol Surg 40 2014 40 45
31. W.H. Clark Jr. A classification of malignant melanoma in man correlated with histogenesis and biologic behavior W. Montagna, F. Hu, Advances in the Biology of the Skin Volume VIII 1967 Pergamon Press New York 621 647
32. W.H. Clark Jr., A.M. Ainsworth, E.A. Bernardino, C.H. Yang Jr., and R.J. Reed The developmental biology of primary human malignant melanomas Semin Oncol 2 1975 83 103
33. D.E. Elder, D. Guerry, M.N. Epstein, and et al. Invasive malignant melanomas lacking competence for metastasis Am J Dermatopathol 6 Suppl 1984 55 61
34. D.I.V. Guerry, M. Synnestvedt, D.E. Elder, and D. Schultz Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent J Invest Dermatol 100 1993 342S 345S
35. M.J. Lin, V. Mar, C. McLean, and J.W. Kelly An objective measure of growth rate using partial biopsy specimens of melanomas that were initially misdiagnosed J Am Acad Dermatol 71 2014 691 697
36. H.G. Welch, and W.C. Black Overdiagnosis in cancer J Natl Cancer Inst 102 2010 605 613
37. M.W. Piepkorn, R.L. Barnhill, D.E. Elder, and et al. The MPATH-Dx reporting schema for melanocytic proliferations and melanoma J Am Acad Dermatol 70 2014 131 141
38. V. Mar, H. Roberts, R. Wolfe, D.R. English, and J.W. Kelly Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia J Am Acad Dermatol 68 2012 568 575
39. P.A. Gimotty, B.P. Van, D.E. Elder, and et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma J Clin Oncol 23 2005 8048 8056
40. W.H. Clark Jr., D.E. Elder, D.I.V. Guerry, and et al. Model predicting survival in stage I melanoma based on tumor progression JNCI 81 1989 1893 1904
41. A. Breslow Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma Ann Surg 172 1970 902 908
42. P.A. Gimotty, D.E. Elder, D.L. Fraker, and et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas J Clin Oncol 25 2007 1129 1134
43. U. Helfenstein, G. Schüler, S. Morf, and D. Schüler Action profiles of predictors of death and survival time in stage I malignant melanoma Dermatology 192 1996 1 7
44. O. Abbas, D.D. Miller, and J. Bhawan Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers Am J Dermatopathol 36 2014 363 379
45. J. Gerdes, U. Schwab, H. Lemke, and H. Stein Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation Int J Cancer 31 1983 13 20
46. B. Lazzaro, and A. Strassburg Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies Hybridoma 15 1996 141 146
47. P. Yazdan, C. Cooper, L.M. Sholl, and et al. Comparative analysis of atypical spitz tumors with heterozygous versus homozygous 9p21 deletions for clinical outcomes, histomorphology, BRAF mutation, and p16 expression Am J Surg Pathol 38 2014 638 645
48. R.Z. Karim, W. Li, A. Sanki, and et al. Reduced p16 and increased Cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors Int J Surg Pathol 17 2009 361 367
49. A.S. McNeal, K. Liu, V. Nakhate, and et al. CDKN2B loss promotes progression from benign melanocytic nevus to melanoma Cancer Discov 5 2015 1072 1085
50. P.A. Van Belle, R. Elenitsas, K. Satyamoorthy, and et al. Progression-related expression of beta3 integrin in melanomas and nevi Hum Pathol 30 1999 562 567
51. M. Pickarski, A. Gleason, B. Bednar, and lT. Duong Orally active alphavbeta3 integrin inhibitor MK-0429 reduces melanoma metastasis Oncol Rep 33 2015 2737 2745
52. J. Guan, R. Gupta, and F.V. Filipp Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma Sci Rep 5 2015 7857
53. L. Ding, M. Kim, K.L. Kanchi, and et al. Clonal architectures and driver mutations in metastatic melanomas PLoS One 9 2014 e111153